Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BMS to Advance F-star Alpha HER2 Therapy | Contract Pharma

What are you searching for?

Sign in
Breaking News

BMS to Advance F-star Alpha HER2 Therapy

Gains exclusive option to acquire F-star Alpha and lead anti-cancer asset

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb and F-star Alpha Ltd. have entered an agreement that provides BMS the exclusive option to acquire F-star Alpha and gain worldwide rights to its lead asset FS102, a Human Epidermal growth factor Receptor 2 (HER2)-targeted therapy in Phase I development for breast and gastric cancer.
 
BMS will make payments totaling $50 million that consist of an option fee for the right to acquire F-star Alpha, certain rights and licenses, and a clinical milestone payment for the Phase I trial. BMS will be responsible for further development of FS102 during the option period, and can exercise the option to acquire F-star Alpha upon starting Phase IIb trials. The total consideration may reach $475 million upon the commencement of a Phase III trial and regulatory approvals in the U.S. and Europe.
 
“This agreement is consistent with our R&D strategy to develop promising treatments that address areas of high unmet medical need, and provides the opportunity to complement our oncology portfolio with a novel targeted therapy,” said Francis Cuss, executive vice president and chief scientific officer, BMS. “We look forward to working with F-star and leveraging our broad clinical expertise in oncology to uncover the full potential of FS102.”
 
“We are thrilled that a company with the oncology experience and expertise of Bristol-Myers Squibb will be advancing our first clinical asset with the potential to provide a significant improvement over the current standard of care for a defined group of patients with HER2-positive cancer,” said John Haurum, M.D., D.Phil., chief executive officer at F-star Biotechnology Ltd. “In addition to the important improvement of cancer therapy FS102 may provide to patients, this program also provides validation of the Modular Antibody Technology platform as a powerful engine to discover and rapidly develop novel targeted biologics.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics